Shrinidhi Nathany/LinkedIn
Dec 16, 2025, 23:14
Shrinidhi Nathany: MRD in AML – From a Test to a Treatment Decision
Shrinidhi Nathany, Consultant Molecular Hematology and Oncology at Fortis Memorial, posted on LinkedIn:
“MRD in AML: From a Test to a Treatment Decision (ELN-DAVID 2025 Update)
Measurable residual disease (MRD) has firmly moved beyond being a laboratory metric.
The 2025 ELN-DAVID consensus update positions MRD as a central clinical decision-making tool in acute myeloid leukemia.
What’s new and practice-changing?
- MRD interpretation is now genetics-specific, aligned with ELN 2022 risk groups
- Introduction of low-level MRD (MRD-LL) and qualitative MRD response categories – Optimal, Warning, High-risk
- Clear linkage of MRD results to clinical action, not just prognosis
- Ultra-high-sensitivity NGS (≤0.01%) now recommended for FLT3-ITD MRD, especially pre-transplant
- Refined, lower thresholds for NPM1 MRD, with clear PB vs BM distinctions
- Explicit caution against misinterpreting CHIP-associated mutations as MRD
Why this matters
- MRD is no longer binary. The same MRD level can mean very different things depending on:
genetics, assay, tissue, and timing. - This framework finally brings context and clarity to MRD-guided decisions.
For clinicians, pathologists, and transplant teams, this update is a must-read and should rapidly translate into:
standardized reporting, multidisciplinary discussion, and more precise patient care.”
Stay informed with Hemostasis Today.
-
Dec 17, 2025, 06:28Wolfgang Miesbach on Linus Völker’s Presentation of Caplacizumab as Frontline Therapy for iTTP
-
Dec 17, 2025, 06:11Lisa Murphy Thanks Stroke Foundation Team for An Impactful, Rewarding and Incredible Year
-
Dec 17, 2025, 06:05Emmanuel J Favaloro Shares A Study on AI and Machine Learning in Thrombosis and Hemostasis
-
Dec 17, 2025, 05:54Michael Bruckman: Fantastic to See Platelet-Inspired Nanoparticles Gaining Attention!
-
Dec 17, 2025, 04:00Peter Verhamme on Genetic Predisposition to Thromboembolism and COVID
-
Dec 16, 2025, 22:16Wolfgang Miesbach – Targeting VEGF to Stop GI Bleeding: Systemic Bevacizumab
-
Dec 16, 2025, 17:14Piotr Czempik Honored for His Work on Cost Reduction in Blood Transfusions
-
Dec 16, 2025, 17:06Davood KHoda Amorzideh on VTE and Bleeding in Cancer
-
Dec 16, 2025, 16:56Kathryn Mikkelsen on The Beat: Vasculearn Network’s Newsletter for Clot Survivors